Form 4: Aeon Biopharma CEO Acquires Restricted Stock Units
SEC Form 4 Filing
Robert E. Bancroft, President & CEO of Aeon Biopharma, acquired 177,103 restricted stock units (RSUs) convertible to Class A Common Stock on May 14, 2025.
Summary
- On May 14, 2025, Robert E. Bancroft, the President & CEO of Aeon Biopharma, Inc., acquired 177,103 restricted stock units (RSUs).
- These RSUs are convertible to Class A Common Stock on a one-to-one basis upon vesting.
- The vesting schedule is 25% on each anniversary of April 29, 2025.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of RSUs to the CEO is a common practice and generally viewed as a positive sign of aligning management's interests with shareholders.
Positives
- The acquisition of RSUs by the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition of RSUs by the CEO could positively impact shareholder confidence.
- Employees may view this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/29/2025 | Date used for the anniversary vesting schedule of the RSUs. |
| 05/14/2025 | Date of the transaction where Robert E. Bancroft acquired 177,103 RSUs. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
Keywords
Aeon Biopharma, Robert E. Bancroft, RSU, Restricted Stock Units, Class A Common Stock, Beneficial Ownership, Form 4, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.